DTIL Profile
Precision Biosciences Inc (DTIL) is a biotechnology company that focuses on developing and commercializing gene editing technology. The company's proprietary ARCUS genome editing platform is a customizable system that uses enzymes to specifically target and edit DNA sequences within cells. This platform is designed to address genetic diseases and other medical conditions by allowing for precise and efficient modification of genes.
Precision Biosciences is currently developing several gene therapies and immuno-oncology treatments using its ARCUS technology. The company's lead product candidate is a gene therapy for the treatment of sickle cell disease, which is currently in Phase 1/2 clinical trials. Precision Biosciences is also working on developing CAR T cell therapies for the treatment of various types of cancer.
In addition to its internal drug development programs, Precision Biosciences has entered into partnerships with several pharmaceutical companies to use its gene editing technology for various applications, including agriculture and industrial biotechnology.
Precision Biosciences was founded in 2006 and is headquartered in Durham, North Carolina. The company went public in March 2019 and is listed on the NASDAQ stock exchange under the ticker symbol "DTIL".
|
